COOPER COMPANIES, INC. COO

Cooper Companies' latest supplied filing rail starts with the June 5, 2026 10-Q and the numbers are blunt: revenue from contracts with customers was $1.08B for the period ending April 30, 2026, while net income attributable to parent was negative $77.9M, operating income was negative $31.0M, and diluted EPS was negative $0.40. The June 4, 2026 8-K says the company issued a press release reporting fiscal second quarter results for the quarter ended April 30, 2026.

The supplied product rail gives the business a concrete centre. CooperSurgical, described in the 10-Q as competing in the fertility and women's health care market, sells a diversified portfolio including fertility products and services, medical devices, and cryostorage such as cord blood and cord tissue. That matters because this is not only a spreadsheet story. It is a medical products and services story where recalls, supply chains, storage obligations, R&D and product mix sit close to the financials.

The balance sheet facts in the supplied 10-Q show assets of $12.48B, liabilities of $4.24B, and stockholders' equity attributable to parent of $8.24B at the period ending April 30, 2026. Cash and cash equivalents were $138.8M, net cash provided by operating activities was $443.7M, payments to acquire property, plant and equipment were $188.6M, R&D expense was $42.5M, and inventory, net, was $896.4M. The same evidence gives weighted average diluted shares outstanding of 195.0M shares.

No chart route is supplied in this evidence pack, so this report does not describe candles, levels, volume, support, resistance or TradingView context. The available market mechanism is the SEC source rail: the 10-Q, two 8-K filings, Form SD, Schedule 13G filings, the SEC filing index, submissions JSON and companyfacts JSON. Those sources establish the filed operating facts and named developments, but they do not prove today’s share price move or market positioning.

The June 4, 2026 8-K also names a product quality development: in December 2023, CooperSurgical initiated a voluntary recall of three specific lots of LifeGlobal embryo culture media. The supplied rail does not quantify the recall impact, but its presence is relevant because it ties the current CooperSurgical story to product controls in fertility care rather than to vague healthcare optimism.

The Form SD filed May 29, 2026 points to a Conflict Minerals Report for the period January 1, 2025 to December 31, 2025, publicly available through the company’s investor corporate governance page. The latest 10-Q also says “Other” products represented less than 1% of net sales in the three and six months ended April 30, 2026 and 2025, giving a narrow product mix detail without enough segment data here to rebuild the revenue bridge.